{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:22:04Z","timestamp":1779895324624,"version":"3.53.1"},"reference-count":44,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,7,8]],"date-time":"2010-07-08T00:00:00Z","timestamp":1278547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To examine the trends in the prescribing of subsidised proton pump inhibitors (PPIs) and histamine receptor antagonists (H<jats:sub>2<\/jats:sub>RAs), in the Australian population from 1995 to 2006 to encourage discussion regarding appropriate clinical use. PPIs and H<jats:sub>2<\/jats:sub>RAs are the second highest drug cost to the publicly subsidised Pharmaceutical Benefits Scheme (PBS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Government data on numbers of subsidised scripts, quantity and doses for PPIs and H<jats:sub>2<\/jats:sub>RAs were analysed by gender and age, dose and indication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measure<\/jats:title><jats:p>Drug utilisation as DDD [defined daily dose]\/1000 population\/day.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The use of combined PPIs increased by 1318%. Utilisation increased substantially after the relaxation of the subsidised indications for PPIs in 2001. Omeprazole had the largest market share but was substituted by its S\u2010enantiomer esomeprazole after its introduction in 2002. There was considerable use in the elderly with the peak use being in those aged 80 years and over. The utilisation of H<jats:sub>2<\/jats:sub>RAs declined 72% over 12 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PPI use has increased substantially, not only due to substitution of H<jats:sub>2<\/jats:sub>RAs but to expansion in the overall market. Utilisation does not appear to be commensurate with prevalence of gastro\u2010oesophageal reflux disease (GORD) nor with prescribing guidelines for PPIs, with significant financial costs to patients and PBS. This study encourages clinical discussion regarding quality use of these medicines. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1969","type":"journal-article","created":{"date-parts":[[2010,7,8]],"date-time":"2010-07-08T11:39:49Z","timestamp":1278589189000},"page":"1019-1024","source":"Crossref","is-referenced-by-count":104,"title":["Marked increase in proton pump inhibitors use in Australia"],"prefix":"10.1002","volume":"19","author":[{"given":"Samantha","family":"Hollingworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,8]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"AIHW Australian GP Statistics and Classification Centre.Gastrointestinal symptoms and management among general practice patients. SAND abstract No. 121 from the BEACH program (Bettering the Evaluation And Care of Health).Supplementary Analysis of Nominated Data. Sydney: AGPSCC University of Sydney. 2008."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01555.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3528(88)80004-6"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2006.100"},{"key":"e_1_2_6_6_2","unstructured":"Department of Health and Ageing.Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. Canberra: Australian Government Publishing Service2007."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2000.00312.x"},{"key":"e_1_2_6_8_2","unstructured":"Canadian Agency for Drugs and Technologies in Health.Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) Program \u2010 Proton Pump Inhibitors2007."},{"issue":"7634","key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","article-title":"Overprescribing proton pump inhibitors","volume":"336","author":"Forgacs I","year":"2008","journal-title":"Br Med J"},{"key":"e_1_2_6_10_2","unstructured":"World Health Organisation.WHO Collaborating Centre for Drug Statistics Methodology 2008."},{"key":"e_1_2_6_11_2","unstructured":"Australian Bureau of Statistics.Population by Age and Sex Australian States and Territories. Cat. No. 3201.0: Australian Bureau of Statistics 2007."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-4286-2"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7280.226"},{"key":"e_1_2_6_14_2","volume-title":"Australian Statistics on Medicines 2006","author":"Australian Government Department of Health and Ageing","year":"2008"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1997.tb125076.x"},{"key":"e_1_2_6_16_2","article-title":"Cost analysis of long\u2010term treatment of patients with symptomatic Gastroesophageal Reflux Disease (GERD) with esomeprazole on\u2010demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland","author":"Szucs T","year":"2008","journal-title":"Value Health"},{"key":"e_1_2_6_17_2","unstructured":"Food and Drug Administration. Esomperazole.Clinical Pharmacology and Biopharmaceutics Review. Appplication Number: 21\u2010153\/21\u2010154. Centre for Drug Evaluation and Research 2001."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2008.tb01918.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldm016"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.142.3.278"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.261"},{"issue":"1303","key":"e_1_2_6_22_2","first-page":"2","article-title":"PPI interactions with clopidogrel","volume":"51","year":"2009","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0810513"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm161"},{"issue":"2","key":"e_1_2_6_25_2","first-page":"38","article-title":"The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis","volume":"101","author":"McGowan B","year":"2008","journal-title":"Ir Med J"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2947"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc066308"},{"issue":"1","key":"e_1_2_6_28_2","first-page":"3","article-title":"Proton pump inhibitors and possible fracture risk","volume":"28","author":"Therapeutic Goods Administration","year":"2009","journal-title":"Australian Adverse Drug Reactions Bulletin"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-0891-4"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.11.014"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02271.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(06)70616-8"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2005.tb06675.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2009.tb02307.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2009.tb02305.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.80"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2004.tb05991.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00332.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.14.1482"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60487-6"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-1-69"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03213.x"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1762.1998.00281.x"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1685"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-006-9031-9"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1969","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T20:55:44Z","timestamp":1696798544000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,8]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1002\/pds.1969"],"URL":"https:\/\/doi.org\/10.1002\/pds.1969","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,8]]}}}